Publications by authors named "Broqua Pierre"

Claim this Profile
B
Biomarkers of Histological Response in Lanifibranor-treated Patients With Metabolic Dysfunction-associated Steatohepatitis.
Jérôme Boursier, Hugo Hervé, Marine Roux, Manal F Abdelmalek, Sven M Francque, Pierre Broqua

Clin Gastroenterol Hepatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lanifibranor and semaglutide demonstrate multiple metabolic benefits in free-choice diet induced obese hamster models of MASH and MetALD.
François Briand, Caroline Dubroca, Guillaume Wettstein, Estelle Grasset, Natalia Breyner, Pierre Broqua

Eur J Pharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD.
Diana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Fernando Bril, Philippe Huot-Marchand, Pierre Broqua

J Hepatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment.
Pierre-Emmanuel Rautou, Shivani Chotkoe, Louise Biquard, Guillaume Wettstein, Denise van der Graaff, Pierre Bedossa, Pierre Broqua

JHEP Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis.
Michael P Cooreman, Javed Butler, Robert P Giugliano, Faiez Zannad, Lucile Dzen, Pierre Broqua

Nat Commun· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers of Glycosaminoglycans (GAG) accumulation in patients with mucopolysaccharidosis type VI-LeukoGAG, Corneal Opacification (COM) and Carotid Intima Media Thickening (CIMT).
Young Bae Sohn, Raymond Wang, Jane Ashworth, Pierre Broqua, Mireille Tallandier

Mol Genet Metab Rep· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models.
Pascale Tuyaa-Boustugue, Ingrid Jantzen, Haoyue Zhang, Sarah P Young, Pierre Broqua

Mol Genet Metab Rep· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas.
Leticia Laura Niborski, Paul Gueguen, Mengliang Ye, Allan Thiolat, Rodrigo Nalio Ramos, Pierre Broqua, Jean-Pierre Quivy

Nat Commun· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas.
Leticia Laura Niborski, Paul Gueguen, Mengliang Ye, Allan Thiolat, Rodrigo Nalio Ramos, Pierre Broqua, Jean-Pierre Quivy

Nat Commun· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Sven M Francque, Pierre Bedossa, Vlad Ratziu, Quentin M Anstee, Elisabetta Bugianesi, Pierre Broqua

N Engl J Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis.
Emma Derrett-Smith, Kristina E N Clark, Xu Shiwen, David J Abraham, Rachel K Hoyles, Pierre Broqua

Arthritis Res Ther· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
Zoe Boyer-Diaz, Peio Aristu-Zabalza, María Andrés-Rozas, Claude Robert, Martí Ortega-Ribera, Pierre Broqua

J Hepatol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study.
Francque Sven M, Bedossa Pierre, Abdelmalek Manal F, Anstee Quentin M, Bugianesi Elisabetta, Broqua Pierre

Contemp Clin Trials· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.
Eugeni Entchev, Ingrid Jantzen, Philippe Masson, Stephanie Bocart, Bruno Bournique, Pierre Broqua

PLoS One· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists.
Jérôme Amaudrut, Maria A Argiriadi, Martine Barth, Eric C Breinlinger, Didier Bressac, Pierre Broqua

Bioorg Med Chem Lett· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.
Benaïssa Boubia, Olivia Poupardin, Martine Barth, Jean Binet, Philippe Peralba, Pierre Dodey, Pierre Broqua

J Med Chem· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.
Jerome Avouac, Irena Konstantinova, Christophe Guignabert, Sonia Pezet, Jeremy Sadoine, Pierre Broqua

Ann Rheum Dis· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis.
Guillaume Wettstein, Jean-Michel Luccarini, Laurence Poekes, Patrick Faye, Francine Kupkowski, Pierre Broqua

Hepatol Commun· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.
Nadira Ruzehaji, Camelia Frantz, Matthieu Ponsoye, Jerome Avouac, Sonia Pezet, Pierre Broqua

Ann Rheum Dis· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.
Julie A Brennan, Radka Graf, Steven M Grauer, Rachel L Navarra, Claudine M Pulicicchio, Pierre Broqua

J Pharmacol Exp Ther· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Marc Princivalle, Pierre Broqua, Richard White, Jessica Meyer, Gaell Mayer

J Pharmacol Exp Ther· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist: part II. In vivo performance.
Grégoire Schwach, Nathalie Oudry, Jean-Pierre Giliberto, Pierre Broqua, Martin Lück

Eur J Pharm Biopharm· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.
Béatrice Sudre, Pierre Broqua, Richard B White, Doreen Ashworth, D Michael Evans

Diabetes· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
Pierre Broqua, Pierre J-M Riviere, P Michael Conn, Jean E Rivier, Michel L Aubert

J Pharmacol Exp Ther· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis